J. J. Sung, J. Y. Lau, G. P. Young, Y. Sano, H. M. Chiu, J. S. Byeon, K. G. Yeoh, K. L. Goh, J. Sollano, R. Rerknimitr, T. Matsuda, K. C. Wu, S. Ng, S. Y. Leung, G. Makharia, V. H. Chong, K. Y. Ho, D. Brooks, D. A. Lieberman and F. K. Chan, “Asia Pacific Consensus Recommendations for Colorectal Cancer Screening,” Gut, Vol. 57, No. 8, 2008, pp. 1166-1176.
 S. K. Maithel and M. I. D'Angelica, “An Update on Random-ized Clinical Trials in Advanced and Metastatic Colorectal Car-cinoma,” Surgical Oncology Clinics of North America, Vol. 19, No. 1, 2010, pp. 163-181.
 M. H. Cohen, J. Gootenberg, P. Keegan and R. Pazdur, “FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-line Treatment of Colorectal Cancer,” Oncologist, Vol. 12, No. 3, 2007, pp. 356-361.
 H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross and F. Kab-binavar, “Bevacizumab Plus Irinotecan, Fluorouracil, and Leu-covorin for Metastatic Colorectal Cancer,” New England Jour-nal of Medicine, Vol. 350, No. 23, 2004, pp. 2335-2342.
 F. Montagnani, C. Migali and G. Fiorentini, “Progression-free Survival in Bevacizumab-based First-line Treatment for Pa-tients with Metastatic Colorectal Cancer: Is It a Really Good End Point?” Journal of Clinical Oncology, Vol. 27, No. 28, 2009, pp. e132-133.
 S. Welch, K. Spithoff, R. B. Rumble and J. Maroun, “Bevaci-zumab Combined with Chemotherapy for Patients with Ad-vanced Colorectal Cancer: A Systematic Review,” Annual On-cology, Vol. 21, No. 6, 2010, pp. 1152-1162.
 J. Capdevila, F. J. Ramos, T. Macarulla, E. Elez and J. Tab-ernero, “The Role of Salvage Treatment in Advanced Colorec-tal Cancer,” Critical Reviews in Oncology/Hematology, Vol. 71, No. 1, 2009, pp. 53-61.
 A. D. Wagner, D. Arnold, A. A. Grothey, J. Haerting and S. Unverzagt, “Anti-angiogenic Therapies for Metastatic Colorec-tal Cancer”. Cochrane Database of Systematic Reviews, No. 3, 2009, pp. CD005392.